Tylenol, a popular over-the-counter pain reliever whose active ingredient is acetaminophen, is made by Kenvue, a spinoff of Johnson & Johnson. In early spring, the company moved its global headquarters to New Jersey, cutting the ribbon on the new location with Gov. Phil Murphy and then-Kenvue CEO Thibaut Mongon.

Kenvue shares rose 6% in premarket trading on Tuesday, set to rebound from a record low hit in the previous session as U.S. President Donald Trump linked its popular pain medication Tylenol to autism.

The White House is reportedly planning to link Tylenol use during pregnancy to autism. The news pushed Kenvue stock down 8%.

The FDA reapproved a GSK drug that stopped being sold more than 25 years ago, as part of a push to identify potential treatments for autism

Kenvue shares declined on Tylenol autism reports, creating a long-term buying opportunity for savvy investors. Click here to read my analysis on KVUE stock.

Medical scholars say, efforts to find a singular cause for autism has historically led to scrutinizing parents and fueling stigma about autism

Donald Trump has doubled down on his advice to pregnant women not to take Tylenol, or acetaminophen.